Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to doravirine/islatravir in virologically suppressed HIV-1
2022-502127-22-00Phase 3Withdrawn
- Sponsor
- Merck & Co.
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of doravirine and islatravir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Merck & Co. Primary endpoints: Virologic failure at Week 48, Adverse events through Week 48 and 1 more. Planned start Apr 2023; status: withdrawn.
02
Drugs
doravirineislatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2022-502127-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502127-22-00.